Clinical trial
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand.
NCT00814957 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand.
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 8, 2008
- Completion date
- June 11, 2009
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
substance dependence